SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom shares recovered from an initial decline following third-quarter results as the company provided an aggressive long-term outlook, projecting AI semiconductor revenue to reach $230 billion by fiscal 2028. While some market participants remain skeptical of the sustainability of this growth and express frustration over the stock's volatility, sentiment has skewed bullish as traders focus on the company's strong guidance and demand from major AI hyperscalers.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares rallied significantly following strong fiscal second-quarter results and an increase to full-year guidance, with investors highlighting rapid enterprise adoption of the company's AI coding assistant as a key growth catalyst. While bulls celebrated the beat and raised outlook, the community remains divided, with skeptics pointing to the company's persistent GAAP losses, high forward price-to-earnings ratio, and heavy stock-based compensation as concerns despite the positive sentiment.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx shares dropped sharply following the failure of its experimental Angelman syndrome drug, apazunersen (GTX-102), to meet its primary and secondary endpoints in a late-stage trial. While some traders express concern over the company's pipeline and cash runway, others view the sell-off as an overreaction, pointing to existing commercial revenue streams and upcoming regulatory catalysts as potential sources of recovery.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology shares dropped sharply following its latest quarterly report, as investors expressed concerns over margin compression and potential slowing in its optical business ramp despite an earnings beat and raised guidance. While some traders view the sell-off as an overreaction that creates a buying opportunity for long-term growth in AI connectivity, others are concerned by the stock's technical breakdown and the potential for further near-term volatility.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is experiencing high volatility as traders react to shifting expectations for Federal Reserve monetary policy and concerns over U.S. debt levels and economic stability. Investors are closely monitoring the potential for rate adjustments, with technical analysts highlighting critical support and resistance levels as the market debates whether the recent move is a sustainable breakout or a temporary correction.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies shares experienced high volatility, surging initially following a strong earnings report and raised annual revenue guidance driven by robust AI server demand, before paring those gains as investors weighed the news against broader market uncertainty. Traders are debating whether the recent price action indicates a broader upward trend or a classic "sell the news" event exacerbated by institutional trading strategies.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending amid volatility surrounding an expanded regulatory review requested by SpaceX regarding its proposed acquisition of Iridium Communications. While retail sentiment remains divided, investors are weighing the long-term potential of the acquisition and the company's end-to-end space capabilities against recent launch delays and concerns over market-wide interest rate risk.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

Investors are focused on Fervo Energy following a major power purchase agreement with Google to supply 396 megawatts of geothermal power by 2028. While bulls highlight this deal as a strong fundamental validation of the company's enhanced geothermal technology for data centers, bears express concerns regarding the company's lack of current profitability, high debt levels, and the extended timeline for project delivery.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are seeing volatility as traders react to the launch of the Muse Spark 1.3 AI model and a favorable court ruling in an antitrust case, though sentiment remains divided by skepticism over high infrastructure spending. Many participants are actively debating whether the stock is undervalued with significant upside potential or a target for a deeper correction amid broader market concerns.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is facing downward pressure as investors digest profit-taking from ARK Invest and concerns regarding the stock's premium valuation following a strong August rally. Traders are also debating the impact of increased litigation risks and recent data handling scrutiny.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics is experiencing significant buying pressure and volatility as investors look ahead to upcoming late-2026 clinical data readouts, specifically for its DM1 and FSHD programs. Traders are closely monitoring the company's recent leadership transition and the potential for a rebound in Elevidys revenue, while strong short interest continues to fuel speculation about a potential short squeeze or buyout.

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will...

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Equity

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.


KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company).Sarepta is a biopharmaceutical company focused on...

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

• Reported GAAP EPS of -$0.05 down -102.49% YoY
• Reported revenue of $401.25M down -34.34% YoY
• Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.

Sarepta Therapeutics experienced a 34% revenue decline due to lower ELEVIDYS sales, incurred a $39 million litigation charge, and faces ongoing regulatory and commercial adoption risks for its product portfolio.

Sarepta Therapeutics achieved quarterly operating profitability, appointed a new CEO with extensive industry experience, and strengthened its financial position with a $197 million increase in cash and investment holdings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Bullish Sentiment

U.S.-Iran conflict escalating

Bond yields (10-yr near 4.8%)

Inflation resurgence

Weak labor market (today's ADP miss)

What&#39;s the biggest risk to the market right now?

Stocktwits

What's the biggest risk to the market right now?

Stocktwits Polls

Traders are closely watching for potential signs of heavy short covering to spark a massive upward price breakout.

The 25 level is viewed as the primary technical hurdle, with investors eagerly monitoring if the price can finally sustain a breakout above it.

Expectation is building around upcoming research and data announcements, particularly regarding pipeline developments and specific disease programs.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRPT Sarepta Therapeutics Inc

Fundamentals

Latest SRPT News